Achieve Life Sciences (ACHV) vs Zevra Therapeutics (ZVRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Achieve Life Sciences (ACHV) has outperformed Zevra Therapeutics (ZVRA) over the past year, gaining 51.9% versus a loss of 8.0%. Over five years, ZVRA leads with a -1.5% price change compared with -20.4% for ACHV. Achieve Life Sciences is the larger company by market cap ($657.8 million vs $590.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACHV | ZVRA |
|---|---|---|
| Share price | $6.38 | $9.94 |
| Market cap | $657.79M | $590.27M |
| 1-day change | -8.46% | -3.21% |
| YTD return | +28.37% | +10.94% |
| 1-year return | +51.90% | -8.01% |
| 5-year return | -20.45% | -1.49% |
| P/E ratio (TTM) | — | 10.80 |
| Forward P/E | — | 9.23 |
| EPS (TTM) | $-1.69 | $0.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $106.47M |
| Revenue growth (YoY) | — | +350.91% |
| Net income (latest FY) | $-54.65M | $83.23M |
| Gross margin | — | 84.52% |
| Operating margin | — | -59.12% |
| Net margin | — | 78.17% |
| 52-week high | $8.64 | $15.04 |
| 52-week low | $2.62 | $8.01 |
| Distance from 52-week high | -26.16% | -33.89% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +121.79% | +151.51% |
| Average volume | 1.41M | 1.07M |
| Shares outstanding | 103.10M | 59.38M |
| Employees | 28 | 61 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACHV has outperformed ZVRA by 59.9 percentage points over the past year.
About Achieve Life Sciences
ACHV stock →Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms.
Healthcare · Biotechnology · 28 employees
About Zevra Therapeutics
ZVRA stock →Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform.
Healthcare · Biotechnology · 61 employees
ACHV vs ZVRA FAQ
Which is bigger, Achieve Life Sciences or Zevra Therapeutics?
Achieve Life Sciences (ACHV) is larger, with a market capitalization of $657.79M compared with $590.27M for Zevra Therapeutics (ZVRA).
Which stock has performed better over the past year, ACHV or ZVRA?
ACHV returned +51.90% over the past 12 months, compared with -8.01% for ZVRA (price return, excluding dividends). Past performance does not predict future results.
Are Achieve Life Sciences and Zevra Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.